U.S. INFLUENZA VACCINES MARKET ANALYSIS

U.S. Influenza Vaccines Market, by Vaccine Type (Trivalent Vaccines, Quadrivalent Vaccines), by Virus Type (Influenza Virus Type A, Influenza Virus Type B), by Age Group (Pediatrics, Adults) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Nov 2022
Code : CMI1127
Pages :120
Formats :
Excel and PDF
Industry : Biotechnology

Market News

U.S. Influenza Vaccines Market: Key Developments

Adoption of inorganic growth strategies such as product approval from regulatory authorities such as U.S. Food and Drug Administration is expected to drive the U.S. influenza vaccines market. For instance, in October 2021, Seqirus USA Inc., a pharmaceutical company, announced that they had received an approval from U.S. Food and Drugs Administration for Quadrivalent influenza vaccine for children of six months and older. Quadrivalent influenza vaccine is the first cell-based influenza vaccine in the U.S. which may have the potential for greater vaccine effectiveness.